Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Vaxart Are Soaring Today

By Zhiyuan Sun – Aug 9, 2021 at 1:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Some encouraging news for this troubled biotech.

What happened?

Shares of clinical-stage vaccine developer Vaxart (VXRT 11.11%) are up again today, gaining 12.34% to $9.83 apiece as of 2:30 p.m. EDT. The stock is up 21% over the past five trading days due to greater capital inflows after the company released encouraging second-quarter earnings on Aug. 5.

Vaxart managed to raise $36.2 million during the quarter via issuing new stock -- bringing its cash balance to $177.3 million. That is quite significant for a company with a market cap just north of $1 billion. In addition, the company received clearance from the U.S. Food and Drug Administration to move into phase 2 clinical trials for its experimental oral coronavirus vaccine. 

An adult puts a mask on a child.

Image source: Getty Images.

So what

The vaccine failed to induce noticeable neutralizing antibody levels in phase 1, leading many investors to abandon the stock. But Vaxart is far from a one-trick pony. With solid funding, the company can diversify its pipeline into other areas to make up for its coronavirus shortfall. Subsequent to Q2, Vaxart signed a worldwide licensing agreement with Altesa Biosciences for its experimental antiviral Vapendavir. If approved, Vaxart could receive up to $130 million in milestone payments before royalties. What's more, it is also running a placebo-controlled booster study to test its norovirus vaccine candidate. 

Now what

The small-cap biotech is still down nearly 60% from its highs in February before clinical data on its coronavirus vaccine candidate came out. The company still has a series of corporate problems that remain unresolved, such as a federal investigation for misrepresenting its role in Operation Warp Speed. Furthermore, even if approved, its coronavirus vaccine candidate is becoming redundant due to an oversupply of authorized vaccines in the country. As a result, I would be careful about getting too excited about the biotech's potential

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Vaxart, Inc Stock Quote
Vaxart, Inc
$1.30 (11.11%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.